Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 5/20 | 0.70 |
| ▸ | CA1 | P00915 | 5/20 | 0.70 |
| ▸ | CA2 | P00918 | 5/20 | 0.70 |
| ▸ | CA7 | P43166 | 5/20 | 0.70 |
| ▸ | CA9 | Q16790 | 5/20 | 0.70 |
| ▸ | CA14 | Q9ULX7 | 5/20 | 0.70 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.70 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.70 |
| ▸ | SIRT1 | Q96EB6 | 2/20 | 0.61 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.60 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.60 |
| ▸ | HPGD | P15428 | 1/20 | 0.60 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.60 |
| ▸ | CASP1 | P29466 | 1/20 | 0.60 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.60 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.53 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.53 |
| ▸ | CES2 | O00748 | 1/20 | 0.52 |
| ▸ | CHRNA7 | P36544 | 4/20 | 0.52 |
| ▸ | GSTA1 | P08263 | 2/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6381759 | 0.91 | CES2 (0.61) | CA12CA1CA2CA7CA9 | |
| SCHEMBL7551903 | 0.91 | CA12 (0.59) | CA12CA1CA2CA7CA9 | |
| SCHEMBL7713693 | 0.89 | GSTA1 (0.67) | CA12CA1CA2CA7CA9 | |
| SCHEMBL7551892 | 0.88 | CA12 (0.61) | CA12CA1CA2CA7CA9 | |
| SCHEMBL7716523 | 0.88 | CA12 (0.61) | CA12CA1CA2CA7CA9 | |
| SCHEMBL30669850 | 0.88 | CA12 (0.61) | CA12CA1CA2CA7CA9 | |
| SCHEMBL29375561 | 0.87 | HDAC1 (0.58) | CA12CA1CA2CA7CA9 | |
| SCHEMBL759926 | 0.87 | HDAC1 (0.58) | CA12CA1CA2CA7CA9 | |
| SCHEMBL6374935 | 0.86 | LIG1 (0.64) | CA12CA1CA2CA7CA9 | |
| SCHEMBL30063097 | 0.86 | LIG1 (0.64) | CA12CA1CA2CA7CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 61 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108602837-A | With the compound and its salt for inhibiting platelet aggregation effect and include its composition for preventing or treating thrombotic diseases | 新丰制药株式会社 | 2018-09-28 | — | — | CN | claimed |
| US-5283324-A | Reacting phenol compound and quinone diazide sulfonyl halide in solvent mixtures of different dielectric constants | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1994-02-01 | — | — | US | claimed |
| CN-108602837-A | With the compound and its salt for inhibiting platelet aggregation effect and include its composition for preventing or treating thrombotic diseases | 新丰制药株式会社 | 2018-09-28 | — | — | CN | disclosed |
| US-20090312313-A1 | COMPOUND HAVING TGFBETA INHIBITORY ACTIVITY AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | KIRIN BEER KABUSHIKI KAISHA (JP) | 2009-12-17 | — | — | US | disclosed |
| US-7560558-B2 | Compound having TGFβ inhibitory activity and medicinal composition containing the same | KIRIN BEER KABUSHIKI KAISHA (JP) | 2009-07-14 | — | — | US | disclosed |
| EP-1724268-A1 | COMPOUND HAVING TGF-BETA INHIBITORY ACTIVITY AND PHARMACEUTICAL COMPOSITION CONTAINING SAME | KIRIN BEER KABUSHIKI KAISHA (JP) | 2006-11-22 | — | — | EP | disclosed |
| US-20060111375-A1 | Compound having tgfß inhibitory activity and medicinal composition containing the same | KIRIN BEER KABUSHIKI KAISHA (JP) | 2006-05-25 | — | — | US | disclosed |
| US-20050233467-A1 | Visible wavelength fluorescent calcium indicators that are (i) leakage resistant and (ii) operate near membranes | INVITROGEN CORP. | 2005-10-20 | — | — | US | disclosed |
| EP-1548008-A1 | COMPOUND HAVING TGF-BETA INHIBITORY ACTIVITY AND MEDICINAL COMPOSITION CONTAINING THE SAME | KIRIN BEER KABUSHIKI KAISHA (JP) | 2005-06-29 | — | — | EP | disclosed |
| US-6383708-B1 | ALKALI SOLUBLE NOVOLAK RESIN AN ESTER OF HYDROXYL GROUPS CONTAINING QUINONE DIAZIDE SULFONIC ACID AND SOLVENTS | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2002-05-07 | — | — | US | disclosed |
| US-6245478-B1 | Resist composition | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2001-06-12 | — | — | US | disclosed |
| EP-0509431-A1 | Process for preparing radiation sensitive compound and positive resist composition | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1992-10-21 | — | — | EP | disclosed |
| US-5130225-A | And alkali soluble resin, a quinone oxazide compound and a hydroxyl containing compound, film thickness retention | SUMITOMO CHEMICAL CO. LTD. (JP) | 1992-07-14 | — | — | US | disclosed |
| EP-0461388-A1 | Positive resist composition | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1991-12-18 | — | — | EP | disclosed |
| EP-0461654-A2 | Radiation-sensitive positive resist composition | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1991-12-18 | — | — | EP | disclosed |
| EP-0460416-A1 | Positive resist composition | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1991-12-11 | — | — | EP | disclosed |
| US-4714657-A | A CURED POLYESTER POLYOL; WEAR AND SOLVENT RESISTANCE; WATER PROOFING THERMOFORMING POLYCARBONATE SURFACES | GENERAL ELECTRIC COMPANY (US) | 1987-12-22 | — | — | US | disclosed |
| US-4598021-A | Weatherable abrasion resistant etherified aminoplast derived coating for plastic substrates | GENERAL ELECTRIC COMPANY (US) | 1986-07-01 | — | — | US | disclosed |
| US-4552936-A | BLEND WITH POLYCAPROLACTONE | GENERAL ELECTRIC COMPANY (US) | 1985-11-12 | — | — | US | disclosed |
| US-4197392-A | Melamine coatings | GENERAL ELECTRIC COMPANY (US) | 1980-04-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060111375-A1 | Compound having tgfß inhibitory activity and medicinal composition containing the same | TGFB1, TGFBR1, TGFBR2 | CA12 1346/4885CA1 1420/4885CA2 906/4885 |
| US-20090312313-A1 | COMPOUND HAVING TGFBETA INHIBITORY ACTIVITY AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | TGFB1, TGFBR1, TGFBR2 | CA12 1133/4885CA1 1419/4885CA2 742/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.